Seeking Alpha

Goldman recommends buying Allergan (AGN +0.2%) on its recent pullback, saying the company is...

Goldman recommends buying Allergan (AGN +0.2%) on its recent pullback, saying the company is well positioned with its diversified portfolio, emerging market exposure, and high growth potential. The firm reiterates its Buy rating with a $106 price target.
Comments (1)
  • If Goldman Sachs is telling you to buy it, it's because they are shorting it!
    25 May 2012, 10:39 AM Reply Like
DJIA (DIA) S&P 500 (SPY)